Table 1. ADVANCE trial results at Week 96

Treatment arm	TAF/FTC+DTG	TDF/FTC+DTG	TDF/FTC/EFV
n	n=351	n=351	n=351
Week 96 Efficacy
HIV RNA <50 copies/mL	276 (78.6%)	275(78.3%)	258 (73.5%)
HIV RNA ≥50 copies/mL	11 (3.1%)	14 (4.0%)	15 (4.3%)
Discontinuation for adverse events	2 (0.6%)	1 (0.3%)	10 (2.8%)
Discontinuation for other reasons	64 (18.2%)	62 (17.7%)	80 (22.8%)
Treatment‐emergent drug resistance	0 (0.0%)	2 (0.6%)	14 (4.0%)
Female mean weight change	+8.1kg	+4.8kg	+3.2kg
Male mean weight change	+5.4kg	+3.6kg	+1.1kg
Treatment emergent obesity	47 (18%)	28 (11%)	18 (8%)
Treatment emergent metabolic syndrome	23 (8%)	16 (6%)	10 (4%)